For millions of people living with type 2 diabetes, the hardest part of managing the condition is not knowing what their blood sugar is doing between finger-prick tests. A major new clinical trial, described as the largest of its kind and published in the New England Journal of Medicine, now suggests that continuous glucose monitors (CGMs) can help even adults who do not use insulin spend roughly five more hours a day within their target blood sugar range.
What the Trial Found
Continuous glucose monitors are small wearable sensors, usually worn on the upper arm or abdomen, that measure glucose in the fluid under the skin every few minutes and send the readings to a phone or receiver. Until recently, they were prescribed mainly to people with type 1 diabetes or to patients with type 2 diabetes who inject insulin several times a day. Everyone else was left with occasional finger-prick checks and a quarterly HbA1c blood test.
The new trial focused on the group that is usually left out: adults with type 2 diabetes who manage their condition with diet, exercise and oral medication rather than insulin. Participants who used a CGM spent about five additional hours a day in the healthy target range compared with those relying on standard care. That is a clinically meaningful difference, because the longer blood sugar stays in range, the lower the long-term risk of damage to the eyes, kidneys, nerves and blood vessels.
Why Five Extra Hours Matters
Diabetes complications rarely come from a single bad day. They build up over years of repeated spikes and crashes that patients often never see. A finger-prick test taken before breakfast cannot reveal the sharp rise after lunch, the slow overnight drift, or the effect of an evening walk. A CGM records all of it, turning guesswork into a continuous picture.
Doctors increasingly use a measure called “time in range” alongside HbA1c, and the World Health Organization notes in its global fact sheet on diabetes that the disease is a leading cause of blindness, kidney failure, heart attacks and stroke. Keeping glucose in range for more hours each day is one of the most practical ways to reduce that risk, and the full trial report is available from the New England Journal of Medicine.
How the Technology Changes Daily Habits
The biggest benefit reported by CGM users is not the device itself but the feedback loop it creates. When people can see, within minutes, how a plate of white rice, a sugary drink or a 20-minute walk changes their glucose curve, their behaviour changes with it. Meals get rebalanced, portions shrink, and activity becomes a tool rather than a chore.
That feedback pairs well with structured exercise. If you are building fitness from zero, our guide to a beginner running plan that takes you from the couch to 5K in eight weeks is a sensible place to start, because regular aerobic activity is one of the most reliable ways to improve insulin sensitivity. Many participants in glucose studies report that seeing their readings improve after exercise is what keeps them consistent.
Who Should Consider a CGM?
Based on the trial, the strongest candidates are adults with type 2 diabetes whose HbA1c remains above target despite medication, people who suspect large post-meal spikes, and anyone who struggles to understand why their readings swing. A CGM may also help people who are newly diagnosed and still learning which foods affect them most.
There are caveats. Sensors cost money, they need replacing every 10 to 14 days, and insurance coverage for people who do not use insulin still varies widely by country and plan. The stream of data can also feel overwhelming at first, and readings should be confirmed with a finger-prick test whenever symptoms do not match the numbers. Anyone considering a device should discuss it with their doctor rather than treating it as a gadget purchase.
The Bigger Picture
The trial lands at a moment when wearable health technology is moving from elite sport into everyday chronic care. Just as digital payments quietly rewired daily life — something we explored in our look at how UPI and digital payments changed everyday money in India — continuous sensors are rewiring how patients and doctors share information. Instead of a three-monthly snapshot, clinicians can now review patterns and adjust treatment with far more precision.
Researchers caution that larger, longer studies are still needed to confirm whether the extra time in range translates into fewer complications over a decade. But the direction is clear: for adults with type 2 diabetes who do not use insulin, continuous glucose monitoring is no longer a niche tool. Five extra hours a day in the target range is a benefit few patients would turn down, and this trial gives doctors the strongest evidence yet for offering it.
